This article is part of the supplement: Proceedings of the 2009 Drug Discovery for Neurodegeneration Conference

Open Access Highly Accessed Proceedings

The basics of preclinical drug development for neurodegenerative disease indications

Karen L Steinmetz† and Edward G Spack†

BMC Neurology 2009, 9(Suppl 1):S2 doi:10.1186/1471-2377-9-S1-S2

No comments have yet been made on this article.

Post a comment